Dr Laiq Ahmed Siddiqui Appointed as Director Clinical Trial Unit at SICHN

Dr Laiq Ahmed Siddiqui has embarked on a significant new chapter as Director of the Clinical Trial Unit at the Sindh Institute of Child Health & Neonatology (SICHN). With over 𝟮𝟱 𝘆𝗲𝗮𝗿𝘀 of leadership experience across the pharmaceutical and healthcare sectors, he will focus on establishing and operationalizing the Clinical Trial Unit, strengthening clinical research capabilities, and developing a connected research network across SICHN’s 13 sites to support better child, newborn, and maternal health outcomes.

Prior to joining SICHN Hospital, Dr. Siddiqui served as Director of Innovation and Development at Pharmatec Pakistan and General Manager of Business Development and Medical Affairs at Aspin Pharma Pvt. Ltd. (An OBS Group Company). His extensive career also includes pharmaceutical strategy, business development, portfolio planning, medical affairs, regulatory affairs, and pharmacovigilance. Alongside his industry leadership, he has served as Visiting Faculty at Dow University of Health Sciences and established Strategic Pharmaceutical & Healthcare Consulting (SPHC), advising organizations on growth strategy, innovation, and commercial excellence.

With deep expertise in pharmaceutical commercialization, clinical research, and healthcare innovation, Dr. Siddiqui brings a strategic vision to advancing evidence-based research and strengthening Pakistan’s clinical research ecosystem.